Focal Onset Seizures
Neurology
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Xenon PharmaceuticalsXEN1101
Xenon PharmaceuticalsXEN1101
Clinical Trials (2)
Total enrollment: 740 patients across 2 trials
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Start: May 2023Est. completion: Dec 2026360 patients
Phase 3Recruiting
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Start: Nov 2022Est. completion: Feb 2026380 patients
Phase 3Completed
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
6h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
6h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
6h ago
Director of Finance
CoMind
London, UK
6h ago
Electronics Engineering Manager
CoMind
London, UK
6h ago
Director of Information Technology
Zavation Medical Products
6h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 740 patients
1 companies competing in this space